Follicular lymphoma international prognostic index

Current Treatment Options in Oncology

Volumn 7, Issue 4, 2006, Pages 270-275

  Solal Celigny, Philippe ^a  

^a CENTRE JEAN BERNARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN P53; RITUXIMAB; TOSITUMOMAB; VINCRISTINE;

ACCURACY; AGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW; STEM CELL TRANSPLANTATION;

HUMANS; LYMPHOMA, FOLLICULAR; NEOPLASM STAGING; PROGNOSIS;

EID: 33745877121     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0036-3     Document Type: Review

References (16)

1. Morton LM, Wang SS, Devesa SS, et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
3. Solal-Celigny P: Prognosis of follicular lymphomas. Clin Lymphoma 2005, 6:21-25.
4. Solal-Celigny P, Roy P, Colombat P, et al.: Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
5. Perea G, Altes A, Montoto S, et al.: Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005, 16:1508-1513.
6. Arcaini L, Colombo N, Passamonti F, et al.: Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 2006, 30:277-282.
7. Colocci N, Weller E, Hochster HS, et al.: Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab [abstract 6526]. J Clin Oncol 2005, 23:566s.
8. Imrie K, Belch A, Pettengell R, et al.: Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma: treatment effect according to baseline prognostic factors [abstract 6525]. J Clin Oncol 2005, 23:566s.
9. Kaminski MS, Coleman M, Lunk BK, et al.: Tositumomab and iodine I 131 tositumomab: efficacy and safety in 141 patients (pts) with previously untreated tow-grade (LG) non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:525s.
10. Montoto S, Lopez-Guillermo A, Altes A, et al.: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004, 15:1484-1489.
11. Wilder RB, Jones D, Tucker SL, et al.: Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001, 51:1219-1227.
12. Colombat P, Salles G, Brousse N, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97: 101-106.
13. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103: 4416-4423.
14. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
15. Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
16. Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711-4716.